Evidence map›Paper›PMID 37435157›Full record

ArticleFrontiers in neurology2023

Case report: Anti septin-5-encephalitis as a treatable cause of cerebellar ataxia and psychiatric symptoms.

Johannes Wischmann, Kathrin Borowski, Joachim Havla, Franziska S Thaler, Tobias Winkler, Tobias Jung, Andreas Straube, Ilias Masouris

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Immunotherapy for autoimmune encephalitis.Cell death discovery · 2025
    Review
  4. Article
  5. Review
  6. Case Presentation of Autoimmune Septin-5 Cerebellar Ataxia.Movement disorders clinical practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Johannes WischmannDepartment of Neurology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Kathrin BorowskiClinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Luebeck, Germany.
Joachim HavlaInstitute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Franziska S ThalerInstitute of Clinical Neuroimmunology, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany.
Tobias WinklerDepartment of Neurology, kbo-Inn-Salzach-Klinikum, Wasserburg am Inn, Germany.
Tobias JungDepartment of Neurology, kbo-Inn-Salzach-Klinikum, Wasserburg am Inn, Germany.
Andreas StraubeDepartment of Neurology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Ilias MasourisDepartment of Neurology, University Hospital, Ludwig-Maximilians-University, Munich, Germany.
Ludwig-Maximilians-Universität München · DEInn-Salzach-Klinikum · DEMunich Cluster for Systems Neurology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Anti-septin-5 encephalitis is a rare disease with only few published cases, mainly based on retrospective CSF and serum analyses. Predominant symptoms are cerebellar ataxia and oculomotor abnormalities. Due to the rareness of the disease, treatment recommendations are scarce. Herein, we prospectively describe the clinical course of a female patient with anti-septin-5 encephalitis. Methods: We describe diagnostic workup, treatment and follow-up of a 54-year-old patient presenting with vertigo, unsteady gait, lack of drive and behavioral changes. Results: Clinical examination revealed severe cerebellar ataxia, saccadic smooth pursuit, upbeat-nystagmus, and dysarthria. Additionally, the patient presented with a depressive syndrome. MRI of the brain and spinal cord were normal. CSF analysis showed lymphocytic pleocytosis (11 cells/μl). Extensive antibody testing revealed anti septin-5 IgG in both CSF and serum without coexisting anti-neuronal antibodies. PET/CT detected no signs of malignancy. Corticosteroids, plasma exchange, and rituximab led to transient clinical improvement followed by relapse. Re-applied treatment with plasma exchange followed by bortezomib resulted in moderate but sustained clinical improvement. Discussion: Anti septin-5 encephalitis represents a rare but treatable and therefore relevant differential diagnosis in patients with cerebellar ataxia. Psychiatric symptoms can be observed in anti septin-5 encephalitis. Immunosuppressive treatment including bortezomib is moderately effective.

Indexed as

autoimmune encephalitisbortezomibcase reportcerebellar syndromeseptin-5

Identifiers

PMID37435157
PMCPMC10331165
OpenAlexW4382060015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.